3/6/2024 0 Comments Catapulting squirrelSo I dug the post into the ground, tacked on the metal to make it rodent-proof, and built a cross-piece on top from which hung too well-stocked bird feeders. I had some old metal ducting stored in the shed that I knew would come into use one day. So, off I went to the local lumber yard to pick up a twelve foot, four by four post and a handful of wood screws. The Ultimate Cottage Daze Squirrel-Proof Bird Feeder Stand! It kind of has a nice ring to it, don’t you think? And with a few minor design modifications of my own, I could take ownership of this little project. Here, however, was a project that perhaps I could take on. She often says that about intricate building or renovation projects around our cottage, though I usually think it is her devious way of making me look foolish. “We (meaning me) could build that,” states my darling wife. The feeders sat atop four by four posts dug into the ground, while old stove piping fixed halfway up prevented squirrels from climbing. He had several bird feeder stands built judiciously around his grounds, easily visible from the back deck. It started with a brilliant idea, one that I stole from a neighbouring cottager. Or what I like to call D.I.Y., to save on my word count. No, it is about the wisdom that I am about to impart to you, the reader, so you too can become the ultimate cottage do-it-yourselfer. This little narrative isn’t about duking it out with a bushy-tailed rodent, or about fighting with nature. What am I going to do at the cottage all summer if I am no longer battling with my sinister rival? And, how will that rascal Chirpy actually win out again in the final paragraph of this column? Well, obviously you haven’t read the title above. Finally, in the end, I have won our on-going battle. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.I have built the ultimate squirrel-proof bird feeder. Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets - patents, jobs, deals, company filings, social media mentions and news - to themes, sectors and companies. Though there is a long way to go before any of these drugs make it to patients, the sheer diversity of treatments and companies developing them makes it likely that new and improved weight loss drugs will enter the market in the coming years. US biotech Fractyl health is developing a GLP-1RA gene therapy that has already been shown to cause lab mice to lose 25% of their body weight. It is also not the only company exploring genetics as a potential route to weight loss. Earlier this month Roche spent $2.7bn to acquire Carmot Therapeutics and its pipeline of GLP-1RA drugs, and in November Astrazeneca signed a deal worth up to $1.82bn with oral GLP-1RA developer Eccogene. Lilly is not the only company spending big to get access to potential new obesity treatments. GlobalData is the parent company of Pharmaceutical Technology. This year, it has become the second most mentioned keyword behind 'revenue'. Lilly is increasingly focused on anti-obesity and diabetes drugs, as demonstrated by the rising number of mentions of 'obesity' in its company filings, per GlobalData analytics. Ideally, understanding the animal’s ability to manipulate its metabolism will help to explain how the metabolic processes of humans are affected by genetics and how to alter these to induce weight loss. By partnering with Fauna, the company aims to discover the secrets of hibernating mammals that are able to reduce their metabolic rate to 1% to 3% of normal in the case of the 13-lined ground squirrel, a focus of Chief Science Officer Katie Grabek’s PhD. Lilly clearly isn’t stopping there though. Lilly is the largest, and its anti-obesity drug Zepbound has proven more effective in clinical trials than Novo’s Wegovy. Obesity drugs have reshaped the pharmaceutical landscape, catapulting current market leader Novo Nordisk from a successful but relatively small Danish diabetes specialist into the second-largest drug company by market cap. The deal is worth up to $494m plus royalties and allows Lilly to utilise Fauna’s Convergence artificial intelligence (AI) platform, which holds biometric data from over 450 mammal species. Pharmaceutical giant Eli Lilly and biotech firm Fauna Bio yesterday (21 December) announced a partnership deal to search for new anti-obesity drugs by examining the hibernation of animals, including the 13-lined ground squirrel.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |